Core Viewpoint - The company, Zhongsheng Pharmaceutical, reported strong financial performance in Q3 2025, driven by its innovative drug, Anladiwei, which is positioned to meet urgent market needs in flu treatment [1][2][4]. Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 1.889 billion yuan, remaining flat year-on-year; net profit attributable to shareholders was 250 million yuan, a significant increase of 68.40% year-on-year; and non-net profit reached 246 million yuan, up 30.36% year-on-year [1]. - In Q3 alone, the company recorded operating revenue of 589 million yuan, representing a year-on-year growth of 8.35%, with non-net profit soaring to 59.03 million yuan, a remarkable increase of 301.03% [1]. Product Innovation - Anladiwei, the world's first drug targeting the PB2 subunit of the influenza virus RNA polymerase, has shown superior efficacy compared to traditional treatments in clinical trials, addressing the urgent need for new flu medications due to rising resistance to existing drugs [2][4]. - The drug's clinical trial results indicate a faster symptom relief time compared to Oseltamivir, and it effectively inhibits resistant strains of the virus, making it a highly anticipated product in the flu treatment market for 2025 [2][3]. Market Opportunities - The drug is currently in the critical stage of entering the medical insurance negotiation process, with expectations of being included in the insurance plan, potentially leading to a nationwide launch by early 2026 [3]. - The flu season is predicted to start earlier this year, with an expected 12.5% increase in daily sales during the peak winter months, contributing to an overall market size of 23.62 billion yuan for flu treatments in 2025 [3]. Strategic Positioning - The company’s strategy of combining traditional Chinese medicine with innovative drug development has created a robust pipeline, including new candidates for respiratory and metabolic diseases, positioning it well for long-term growth [4][5]. - The dual technology platform of small molecules and peptides has established a competitive edge in research and development, enabling the company to navigate industry cycles effectively [4].